Table 2 Progression and seeding models in uni- and multivariate Cox-regression analysis in three cohorts (TCGA,Taylor, and Long)

From: Exploring the transcriptome of hormone-naive multifocal prostate cancer and matched lymph node metastases

Progression model
  Univariate Multivariate
Variable Characteristics HR P-value C-index HR P-value C-index C-index*
TCGA (n = 405, 58 BCR)         
 PSA Continuous 1.03 (1.01–1.04) 4.60E−03 0.610
 Margin status Pos. vs. neg. 1.30 (0.77–2.19) 3.30E−01 0.519
 Gleason score >7 vs. ≤7 3.79 (2.10–6.84) 9.38E− 06 0.642 2.07 (1.10–3.91) 2.42E−02 0.725 0.673
 Tumour stage pT3 vs. pT2 5.18 (2.22–12.11) 1.46E−04 0.624 3.15 (1.29–7.70) 1.20E−02   
 Progression score Continuous 2.61 (1.63–4.18) 7.08E−05 0.672 2.09 (1.29–3.37) 2.66E−03   
Taylor (n = 107, 13 BCR)         
 PSA Continuous 1.04 (0.99–1.10) 9.32E−02 0.671
 Margin status Pos. vs. neg. 3.14 (1.02–9.69) 4.66E−02 0.653 4.32 (1.37–13.65) 1.26E−02 0.870 0.653
 Gleason score >7 vs. ≤7 8.66 (2.49–30.28) 6.92E−04 0.670   
 Tumour stage pT3 vs. pT2 2.83 (0.91–8.78) 7.25E−02 0.639   
 Progression score Continuous 5.66 (2.05–15.64) 8.29E−04 0.829 5.64 (2.11–15.07) 5.63E−04   
Long (n = 91, 40 BCR)         
 PSA Continuous 1.10 (1.07–1.13) 1.61E−09 0.719 1.09 (1.05–1.12) 3.85E−07   
 Margin status Pos. vs. neg. 3.29 (1.73–6.27) 2.92E−04 0.649 2.31 (1.16–4.61) 1.67E−02   
 Gleason score >7 vs. ≤7 2.71 (1.24–5.93) 1.24E−02 0.575   
 Tumour stage pT3 vs. pT2 1.90 (0.85–4.29) 1.20E−01 0.562   
 Progression score Continuous 2.33 (1.27–4.28) 6.80E−03 0.628 1.72 (0.98–3.04) 5.96E−02   
  1. Significant P values (P< 0.05) are highlighted in bold
  2. C-index = Harrell’s C-index for final model including progression model (top) or seeding model (bottom)
  3. C-index* = Harrell’s C-index for final model excluding progression model (top) or seeding model  (bottom)
Seeding  model
  Univariate Multivariate
Variable Characteristics HR P-value C-index HR P-value C-index C-index*
TCGA (n = 405, 58 BCR)         
 PSA Continuous 1.03 (1.01–1.04) 4.60E−03 0.610
 Margin status Pos. vs. neg. 1.30 (0.77–2.19) 3.30E−01 0.519
 Gleason score >7 vs. ≤7 3.79 (2.10–6.84) 9.38E−06 0.642
 Tumour stage pT3 vs. pT2 5.18 (2.22–12.11) 1.46E−04 0.624 3.70 (1.55–8.84) 3.17E−03 0.722 0.624
 Seeding score Continuous 2.39 (1.81–3.16) 1.05E−09 0.705 2.01 (1.51–2.69) 2.46E−06   
Taylor (n = 107, 13 BCR)         
 PSA Continuous 1.04 (0.99–1.10) 9.32E−02 0.671
 Margin status Pos. vs. neg. 3.14 (1.02–9.69) 4.66E−02 0.653 4.77 (1.52–15.01) 7.52E−03 0.785 0.653
 Gleason score >7 vs. ≤7 8.69 (2.49–30.28) 6.92E−04 0.670   
 Tumour stage pT3 vs. pT2 2.83 (0.91–8.78) 7.25E−02 0.639   
 Seeding score Continuous 4.31 (1.94–9.57) 3.37E−04 0.777 4.85 (2.17–10.86) 1.23E−04   
Long (n = 91, 40 BCR)         
 PSA Continuous 1.10 (1.07–1.13) 1.61E−09 0.719 1.12 (1.08–1.16) 3.15E−09 0.807 0.719
 Margin status Pos. vs. neg. 3.29 (1.73–6.27) 2.92E−04 0.649   
 Gleason score >7 vs. ≤7 2.71 (1.24–5.93) 1.24E−02 0.575   
 Tumour stage pT3 vs. pT2 1.90 (0.85–4.29) 1.20E−01 0.562   
 Seeding score Continuous 2.79 (1.80–4.34) 4.86E−06 0.704 2.70 (1.78–4.10) 3.27E−06   
  1. Significant P values (P< 0.05) are highlighted in bold
  2. C-index = Harrell’s C-index for final model including progression model (top) or seeding model (bottom)
  3. C-index* = Harrell’s C-index for final model excluding progression model (top) or seeding model  (bottom)